Final Distribution - After 12 long years this BK should be completely done now. You should have received a fourth and final distribution of just over a cent on about 3/20/20. This represents the remaining assets since they discontinued the D&O claims. It would have been phenomenal if they were successful in their litigation but unfortunately they were not.

Another small distribution will be coming up in a few months. They decided to drop the last lawsuit so they will be distributing the remainder of the assets.

Thanks I was figuring they would pay us more but I wish they wouldn't take so long

The last distribution was a mistake. No one could give me a definitive answer but I expect there to be another distribution in the next few weeks and it should be higher than the one they just took back. May be around a penny or just over (.01-.0135.).

Hi Jet. I will investigate and let you know what I find out.

I received a dividend like two months and they reversed it on the 07/18/18? Are they going to pay higher dividend?

A small distribution is coming soon to shareholders. Small possibility of more coming.

Is anyone else still following this stock like me? Just curious...

IMMCQ Finra deleted symbol:

http://www.otcbb.com/asp/dailylist_detail.asp?d=07/24/2014&mkt_ctg=NON-OTCBB

~ $IMMCQ ~ Daily Par Sar Buy Signal ~ Criteria alert triggered during a recent trading session!

$IMMCQ has just triggered the "Parabolic SAR Buy Signals" scan criteria at Stockcharts.com
~ http://tinyurl.com/SAR-BUY ~







For a more in Depth study and DD profile, similar to the one contained in this link: ~ http://tinyurl.com/DDexample ~
Click the following link and type ticker or brief message asking me about the DD: ~ http://tinyurl.com/GET-THE-DD ~

What does the scan "Parabolic SAR Buy Signals" mean? Below is an image example and study link.
~ http://stockcharts.com/school/doku.php?id=chart_school:technical_indicators:parabolic_sar ~


To find other similar posts of "IMMCQ" utilize the links that follow.
Search MACDgyver's "Parabolic SAR Buy Signals" posts: ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=ParSarBuyScan ~
Search MACDgyver's posts for symbol "IMMCQ": ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=IMMCQ ~
Search Ihub for "IMMCQ" posts: ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=IMMCQ ~


For more in depth training and information visit Chartschool on the Stockcharts page.
~ http://stockcharts.com/school/doku.php?id=chart_school ~


Also don't forget the Ihub Edu Channel.
~ http://investorshub.advfn.com/boards/education.aspx ~


c

ImmuCell's Mastitis Drug Meets Pivotal Effectiveness Study End Point
Press Release
Source: ImmuCell Corporation
On Wednesday September 30, 2009, 8:00 am EDT
Companies:ImmuCell Corp.
PORTLAND, ME--(Marketwire - 09/30/09) - ImmuCell Corporation (NASDAQ:ICCC - News) today announced initial results from its pivotal effectiveness study of Mast Out�. All data, results and conclusions discussed in this press release are subject to review and approval by the U.S. Food and Drug Administration (FDA), Center for Veterinary Medicine.

In a study of approximately 300 qualified cows with subclinical mastitis that was conducted at sixteen sites across the United States, the Mast Out� treatment group showed a statistically highly significant (p < 0.0001) overall cure rate in comparison to the placebo group. The preliminary breakdown of the data by species suggests both the necessary numerical superiority and clinical relevancy to support robust product performance in the field. The primary objective of this study was to demonstrate effectiveness in the field, at a level similar to currently marketed intramammary antibiotics.

"We accomplished our objective and confirmed results from two major field studies conducted since 2003," commented Michael F. Brigham, President and CEO. "The main competitive advantage of Mast Out� is that it may qualify for use in the United States without a requirement to discard milk or withhold meat from human consumption for the period of treatment and for a defined period of time thereafter. All mastitis treatment products on the market today are sold subject to such 'discard' and 'withhold' requirements."

These positive results justify a continued product development effort. Commercial introduction of Mast Out� in the United States is subject to review and approval of a New Animal Drug Application (NADA) by the FDA, which approval cannot be assured. The NADA is comprised of several Technical Sections under the FDA's phased review of a NADA. The pivotal effectiveness data described in this press release would be used to prepare the submission of the Effectiveness Technical Section. The current objective is to complete all the Technical Sections required for submission of the administrative NADA to the FDA in approximately 12 months. The Company intends to continue disclosing the current status of each Technical Section in its periodic filings with the Securities and Exchange Commission.

By acquiring certain rights and patents in April 2000, ImmuCell began its development of Mast Out�, which is an intramammary infusion product containing Nisin for the treatment of subclinical mastitis in lactating dairy cows. The dual purpose of such a subclinical treatment would be to both clear the infection at an early stage and earn premiums for higher quality milk (low Somatic Cell Counts). The use of antibiotics in food-producing animals may be a contributing factor to the rising human public health problem of bacterial drug resistance. As an alternative to traditional antibiotics that are on the market, Mast Out� could potentially reduce the use of traditional antibiotics in the treatment of mastitis.

Preparations for this pivotal effectiveness study included the production of registration batches of drug product to fulfill the pivotal regulatory requirements of effectiveness, target animal safety, and stability at no less than 10% of the scale anticipated for commercial manufacture. The treatment phase of this study was initiated in June 2008.

Nisin, the same active ingredient contained in ImmuCell's product, Wipe Out� Dairy Wipes, is an antibacterial peptide that is commonly used as a preservative in dairy food products. Nisin is known to have activity against most gram positive and some gram negative bacteria.

ImmuCell Corporation is a public, animal health biotechnology company dedicated to developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at http://www.immucell.com.

IMMC files Chapter 11.

Manny

Veridex Announces Agreement to Acquire the Assets of Immunicon Corporation
Wednesday June 11, 9:00 am ET

RARITAN, N.J., June 11 /PRNewswire-FirstCall/ -- Veridex, LLC announced today that it has signed an asset purchase agreement to acquire substantially all of the assets of Immunicon Corporation (OTC Bulletin Board: IMMC - News) for $31 million in cash subject to certain closing date adjustments, plus the discharge and release of certain claims owing to Veridex, LLC and the assumption of certain specified liabilities.
Maybe up 300-400%
The assets to be acquired include intellectual property, product inventory and clinical data as well as all technologies related to the CellSearch(TM) System, the first diagnostic test to automate the detection and enumeration of circulating tumor cells (CTCs), cancer cells that detach from solid tumors and enter the blood stream. The CellSearch(TM) System is currently cleared for the prognosis and monitoring of patients with metastatic breast, metastatic colorectal and metastatic prostate cancer.

"This agreement represents a strategic opportunity for Veridex to continue to bring innovative diagnostic tests to the patients, physicians and laboratories involved in the fight against cancer," said Ken Berlin, General Manager, Veridex, LLC.

Veridex and Immunicon have partnered since 2000 to develop and commercialize novel cancer diagnostic platforms and products.

The transaction is subject to the approval by the bankruptcy court overseeing Immunicon's bankruptcy case. It is not expected to require anti-trust review or shareholder approval.

Thx
MK

Any thoughts on this now ?
thx
MK

This thing is blowing up today. Great news!!!

Taken right from the Yahoo Finance Home Page.........

Yahoo! Finance Essentials
Community Sentiment Popular Stories Stocks everyone is talking about.

Bullish
Tessera Technologies Inc. (TSRA)
Immunicon Corp. (IMMC)
Kongzhong Corp. (KONG)

Bearish
Potash Corp. of Saskatchewan, Inc. (POT)
American Capital Strategies, Ltd. (ACAS)
Vasogen Inc. (VSGN)

Data provided by Collective Intellect, Inc.

Sure does...big buys coming in...should explode back up!

It was 1.43 after announcement of FDA clearance! This is not a big deal!

They lost the lawsuit. Panic selling this am. I would not sell at this level. Co has value far beyond this dark day.

eom

ALL over it surf!! PATIENCE does payoff!!!!!! Mbd

Immunicon Corporation Announces FDA Clearance of the CellSearch(TM) Circulating Tumor Cell Kit for Monitoring Patients with Metastatic Prostate Cancer
Wednesday February 27, 6:06 pm ET
Diagnostic Test Is Now Cleared for Three of the Four Most Common Cancers

HUNTINGDON VALLEY, Pa.--(BUSINESS WIRE)--Immunicon Corporation (NASDAQ:IMMC - News) announced today that the FDA has cleared the CellSearch™ Circulating Tumor Cell (CTC) Kit as an aid in the monitoring of patients with metastatic prostate cancer. A sample of the patient’s blood is processed with the CellSearch Kit using the CellTracks® System to capture and count CTCs. This clearance represents another expansion to claims for the kit, which is now cleared for three of the four most prevalent cancers. The CellSearch CTC kit was originally cleared in January 2004 to predict progression-free and overall survival in patients with metastatic breast cancer and later expanded to include monitoring. In November 2007, the kit was cleared by the FDA for monitoring metastatic colorectal cancer.

Byron D. Hewett, CEO and President of Immunicon Corporation, commented, "Because the three pivotal trials demonstrated that the CellSearch test predicts survival in prostate, breast and colorectal cancers, circulating tumor cell testing should become standard of care in the management of patients with metastatic disease. We estimate the market size for testing in these three cancers is almost $1 billion. More importantly, oncologists can use the results to make better-informed treatment decisions and improve patient care for three of the top carcinomas.”

THE IMPACT

According to the American Cancer Society, prostate cancer claims approximately 27,000 lives each year, the vast majority of which are a result of recurrent metastatic disease. Metastatic prostate cancer occurs when tumor cells spread to other locations in the body and grow. Evaluation of CTC count at any time during the treatment of metastatic disease allows assessment of patient prognosis and predicts survival. Oncologists often have to wait several months before they can determine if a specific treatment is beneficial to the patient. Changes in CTC count can be assessed in 3-5 weeks, rather than in the 8-12 weeks required for imaging studies such as CT scans. The results of serial CTC testing can help physicians assess disease progression, thereby guiding more informed patient care decisions earlier.

THE RESULTS

The study demonstrated that a threshold of 5 CTC / 7.5 mL stratifies androgen independent prostate cancer patients into two distinct groups based on comparison to overall survival (OS). Patients with 5 or more CTCs at baseline and at 3-4 weeks after the initiation of chemotherapy have significantly shorter OS than patients with less than 5 CTCs. The presence of CTCs at any time during the course of the disease is a strong independent predictor of OS. The CellSearch test provides more reliable and informative results regarding the biological activity of the individual patient’s disease status than do measurements of PSA. Although a reduction of PSA at some points after initiation of therapy may reach significance for prediction of survival, favorable CTC at any time point were more accurate than the PSA evaluation. The practical implication is the use of CTC analysis for the evaluation of the probability of survival of patients with metastatic prostate cancer. In cases where CTC and PSA change were discordant, CTC change provided the most accurate assessment of prognosis.

Finally, the fundamental principles of tumor biology upon which the CellSearch test is based are common to all three diseases. Consequently, results from each study demonstrate that a CTC threshold exists in these carcinomas and can be used to stratify patients based on the demonstrated agreement of CTC with the true clinical end point overall survival.

For more details on the results of this prostate cancer trial, please refer to the press release section of the Immunicon web site (immunicon.com) and download the release entitled "Immunicon Achieves Endpoint in its Pivotal Clinical Trial in Metastatic Androgen Independent Prostate Cancer" posted on January 18, 2007.

The CellSearch Circulating Tumor Cell Kit was developed by Immunicon and is exclusively marketed by Veridex, LLC, in the cancer field.

Form 8-K for IMMUNICON CORP
----------------------------------------------------------------
25-Jan-2008
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Tr

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Standard; Transfer of Listing.
On January 23, 2008, Immunicon Corporation ("Immunicon") received notice from The Nasdaq Stock Market, Inc. ("Nasdaq") that the minimum bid price of its common stock had fallen below $1.00 for the last 30 consecutive business days and that its common stock is, therefore, subject to delisting from the Nasdaq Capital Market. Nasdaq Marketplace Rule 4310(c)(4) requires a $1.00 minimum bid price for continued listing of an issuer's common stock.

In accordance with Nasdaq Marketplace Rule 4310(c)(8)(D), Immunicon has until July 21, 2008 (180 calendar days from January 23, 2008) to regain compliance. No assurance can be given that Immunicon will regain compliance during that period.

Immunicon can regain compliance with the minimum bid price rule if the bid price its common stock closes at $1.00 or higher for a minimum of 10 consecutive business days during the initial 180-day period, although Nasdaq may, in its discretion, require an issuer to maintain a bid price of at least $1.00 per share for a period in excess of ten consecutive business days (but generally no more than 20 consecutive business days) before determining that the issuer has demonstrated the ability to maintain long-term compliance. If compliance is not achieved by July 21, 2008, Immunicon will be eligible for another 180-day compliance period (until January 17, 2009) if it meets the Nasdaq Capital Market initial listing criteria as set forth in Nasdaq Marketplace Rule 4310(c) other than the minimum bid price requirement. No assurance can be given that Immunicon will be eligible for the additional 180-day compliance period or, if applicable, that it will regain compliance during any additional compliance period.





Item 7.01. Regulation FD Disclosure.
On January 25, 2008, Immunicon issued a press release announcing that it received notice from Nasdaq that the minimum bid price of its common stock had fallen below $1.00 for the last 30 consecutive business days and that its common stock is, therefore, subject to delisting from the Nasdaq Capital Market. A copy of the press release is furnished herewith as Exhibit 99.1.





Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.

99.1 - Press release dated January 25, 2008.

AGREED!!

Morning, Once IMMC starts to move up it should be quick and sharp, the stock is so thinly traded that it could double with a 2or3 day move.

GLTY

Hello surf we have many of the same idealogy.(smile) I believe we are VERY close to the bottom here. Also IMMU as well GLTUS!

Immunicon Corporation Announced the Filing for FDA Clearance of the CellSearch(TM) Circulating Tumor Cell Kit for Monitoring Patients with Metastatic Androgen-Independent Prostate Cancer
Monday December 3, 7:00 am ET

HUNTINGDON VALLEY, Pa.--(BUSINESS WIRE)--Immunicon Corporation (NASDAQ-GM:IMMC) announced today that it filed with the FDA a request for clearance of the CellSearch™ Circulating Tumor Cell Kit as an aid in the monitoring of patients with metastatic androgen-independent prostate cancer.

Immunicon announced that it had successfully met the primary endpoint associated with its pivotal clinical trial in metastatic androgen-independent prostate cancer in January 2007. The primary endpoint required demonstrating that circulating tumor cells (CTC) levels three-to-five weeks after the initiation of chemotherapy predict overall survival.

The study results which were presented by Jose Moreno, MD, clinical associate professor of Urology at Thomas Jefferson University at the 43rd Annual American Society of Clinical Oncology (ASCO) meeting in June also showed that CTC levels predict overall survival at each of the additional monthly time points tested. Results showed that serial CTC measurement before and after initiation of therapy in men with androgen-independent prostate cancer delivered more reliable information about disease progression and patient survival months earlier than the traditional measurement of changes in Prostate-Specific Antigen (PSA) measurements.

Byron D. Hewett, CEO and President of Immunicon Corporation commented, "Research and clinical testing have continued to prove the effectiveness and impact the CellSearch™ Circulating Tumor Cell Test can have in the treatment of patients with metastatic disease. With CellSearch’s current FDA clearances for breast and colorectal cancers, adding the clearance for metastatic androgen-independent prostate cancer potentially will provide oncologists and pharmaceutical companies an additional tool to develop therapeutics and improve patient care for three of the top carcinomas.”

For more details on the results of this prostate cancer trial, please refer to the press release section of the Immunicon web site and download the release entitled "Immunicon Achieves Endpoint in its Pivotal Clinical Trial in Metastatic Androgen Independent Prostate Cancer" posted on January 18, 2007.

The CellSearch Circulating Tumor Cell Kit, developed by Immunicon, is exclusively marketed by Veridex, LLC, in the cancer field.

http://biz.yahoo.com/bw/071203/20071203005357.html?.v=1

CellSearch(TM) Circulating Tumor Cell Kit Receives FDA Clearance for Monitoring Patients with Metastatic Colorectal Cancer
Monday November 26, 7:00 am ET
Data is consistent with that seen in breast cancer and broadens the clinical utility of the CellSearch test

HUNTINGDON VALLEY, Pa.--(BUSINESS WIRE)--Immunicon Corporation (NASDAQ-GM:IMMC) announced today that FDA clearance has been received for the CellSearch™ Circulating Tumor Cell Kit as an aid in the monitoring of patients with metastatic colorectal cancer. The CellSearch test was originally cleared in 2004 for in vitro diagnostic use in patients with metastatic breast cancer. Serial testing for circulating tumor cell (CTC) count should be used in conjunction with other clinical methods for monitoring colorectal or breast cancer. Evaluation of CTC count at any time during the course of disease allows assessment of patient prognosis and is predictive of progression free survival and overall survival. The CellSearch Circulating Tumor Cell Kit, developed by Immunicon, is exclusively marketed by Veridex, LLC, in the cancer field.

The colorectal cancer trial was a prospective, multi-center study designed for longitudinal enumeration of CTCs in patients with metastatic colorectal carcinomas measurable by imaging. A total of 430 evaluable patients were enrolled into the trial between February 2004 and February 2006, from a total of 55 sites in the United States and Europe. Imaging studies were performed prior to the initiation of therapy and at subsequent intervals of approximately 6-12 weeks. CTCs were measured at baseline, 1-2 and 3-5 weeks after the initiation of therapy, and at the time of all subsequent imaging studies (approximately every 6-12 weeks) using Immunicon’s CellTracks® technology. Metastatic colorectal cancer patients remained on the study and provided blood for up to 12 months or until documented evidence of disease progression and/or death. Long-term survival information is being obtained on all patients by medical record review at periodic intervals for up to 24 months after study completion.

Consistent with the data in metastatic breast cancer, CTCs predict survival at multiple time points during the course of therapy. Patients with 3 or more CTCs at any of the time points had a much higher likelihood of dying sooner than patients with less than 3 CTCs. For example, at the 3-5 week time point, patients with 3 or more CTCs had a median survival of 4.4 months, whereas patients with less than 3 has median survival of 16.4 months. This represents a 3.7-fold difference in survival.

Furthermore, the trial showed that changes in CTC count during therapy are significant. Patients with 3 or more CTCs prior to treatment who dropped to less than 3 CTCs had a median survival of 11.7 months, which is a significant improvement in survival when compared to patients whose CTC count remained above 3 for the duration of the trial, where the median survival was only 3.9 months. Patients who started with less than 3 and converted to 3 or more CTCs had a median survival of 7.1 months. Patients with less than 3 CTCs throughout the study had the highest median survival (18.6 months).

Leon Terstappen, chief scientific officer of Immunicon commented, “The new FDA-cleared claims in metastatic colorectal cancer are very important because the clinical utility of CTC counts is validated in a second major carcinoma. The CellSearch test represents an additional tool for oncologists to manage their patients with objective information much sooner than currently available CT imaging.”

Byron Hewett, president and CEO of Immunicon said, “We are pleased to add another carcinoma claim to the CellSearch™ package insert. We look forward to adding claims in prostate cancer by mid-2008.”

http://biz.yahoo.com/bw/071126/20071126005214.html?.v=1

Immunicon Corporation Reports Results for the Three and Nine Months Ended September 30, 2007
Friday November 2, 7:00 am ET
Updates Estimated Financial Outlook for the Year 2007

HUNTINGDON VALLEY, Pa.--(BUSINESS WIRE)--Immunicon Corporation (Nasdaq-Global Market:IMMC), which is developing and commercializing proprietary cell and molecular-based human diagnostic and life-science research products with a primary focus on cancer, today announced its results of operations for the three and nine month periods ended September 30, 2007.

On May 31, 2007, Immunicon announced that it had filed a Demand for Arbitration against Veridex, LLC, a wholly-owned subsidiary of Johnson and Johnson, or Veridex, whereby Immunicon is seeking termination of the 20-year exclusive worldwide agreement with Veridex, which currently grants Veridex the right to market, sell and distribute its cancer diagnostic products; rescission of all licenses currently held by Veridex under that agreement; and payment of compensatory and punitive damages based on, “repudiation and fundamental breaches by Veridex of its contractual, agency and other fiduciary obligations to market, sell and distribute Immunicon's cancer diagnostic products.” It is anticipated that this arbitration will be completed before the end of the first quarter of 2008.

Immunicon reported product and service revenue of $4.7 million for the three months ended September 30, 2007, which represented a 160% increase over the $1.8 million in product and service revenue for the three months ended September 30, 2006. Instrument revenue was $3.3 million in the third quarter of 2007 compared to $1.0 million in the third quarter of 2006. Reagent and consumable product sales were $743,000 in the three months ended September 30, 2007 and $488,000 in the three months ended September 30, 2006. Service revenue increased by 107% to $588,000 in the third quarter of 2007 compared to $283,000 in the same period in 2006.

Immunicon delivered 22 CellTracks AutoPrep sample preparation instruments and 23 CellTracks Analyzer II instruments to customers during the quarter ended September 30, 2007 and now has 119 AutoPrep instruments and 130 cell analyzers in service. An instrument system is comprised of one cell analyzer plus one AutoPrep sample preparation device. As of September 30, 2007, we have an instrument backlog of 10 instrument systems. Recognition of revenue related to instrument shipments to customers typically is delayed for a period of several months pending the final evaluation and acceptance of these instruments by customers.

Costs of goods sold were $4.4 million for the three months ended September 30, 2007 compared to $1.9 million for the three months ended September 30, 2006. Immunicon reported a gross profit on product and service sales of $252,000 in the third quarter of 2007 compared to a loss on product sales of $151,000 in the quarter ended September 30, 2006. The gross profit on sales of products and services in the quarter ended September 30, 2007 reflects margin on instrument sales of $233,000 and on services of $276,000 offset by a loss on reagent and consumable sales of $257,000. We completed the outsourcing of our instrument manufacturing activities in the third quarter. Effective April 1, 2007, we increased the list prices for our instruments to $205,000 per instrument system from $150,000. As a result, the gross profit per instrument for the quarter was approximately $6,000.

Research and development expenses for the three months ended September 30, 2007 were $2.6 million compared to $3.1 million in the corresponding three months in 2006. The reduction of $500,000 was principally a result of the decrease in clinical trial and development costs and the utilization of certain research and development personnel to support pharma services activity. The salary cost related to support of pharma services activity is charged to cost of goods sold.

General and administrative (“G&A”) expenses for the quarter ended September 30, 2007 were $6.8 million, compared to $2.7 million for the comparable quarter of 2006. This increase is attributable principally to increases in legal and professional fees of $4.5 million related to our arbitration against Veridex. As of September 30, 2007, we have incurred $5.4 million in costs related to the arbitration.

As disclosed previously, Immunicon issued an aggregate of $30,000,000 in principal amount of unsecured subordinated convertible notes (the “Notes”) and received $27.3 million in proceeds net of related fees and expenses on December 5, 2006. As a result of this financing, Immunicon values certain provisions of the Notes and the related warrants separately in accordance with various accounting guidance documents, including Statement of Financial Accounting Standards 133, “Accounting for Derivative Instruments and Hedging Activities”, and related interpretations including EITF 00-19, “Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock.” Upon issuance of the Notes, Immunicon recorded a liability of $8.1 million related to the embedded conversion option in the Notes and a liability of $1.9 million related to the value of the warrants. For the quarter ended September 30, 2007, Immunicon has marked-to-market the conversion option and the warrants and have recorded a non-cash increase in income of $3.3 million in the Consolidated Statement of Operations related to the change in valuation of the Notes and the related warrants for the three months ended September 30, 2007. For further description of the Notes and related warrants, please refer to the Current Report on Form 8-K filed by Immunicon with the Securities and Exchange Commission on December 5, 2006.

Interest expense was $1.5 million and $98,000 for the three months ended September 30, 2007 and 2006, respectively. The increase is attributable principally to the non-cash interest expense of $1.5 million related to the issuance of the Notes and related warrants. Interest income was $514,000 and $367,000 for the three months ended September 30, 2007 and 2006, respectively. The increase in 2007 was due to the higher available cash balance for investment in 2007.

For the three months ended September 30, 2007, Immunicon’s net loss was $6.7 million compared to a net loss of $5.6 million for the three months ended September 30, 2006. The loss per share was $0.24 and $0.20 for the three months ended September 30, 2007 and September 30, 2006, respectively. The weighted average common shares outstanding was 27.7 and 27.6 million, respectively, for the three month periods ended September 30, 2007 and September 30, 2006, respectively.

As of September 30, 2007, Immunicon had cash, cash equivalents and investments of $38.6 million.

Financial guidance update

Immunicon is updating its previously announced financial guidance for the year ending December 31, 2007:

* Instrument system placements (a system includes one CellTracks Analyzer II and one CellTracks AutoPrep System) - range of between 65 and 75 system placements
* CellTracks AutoPrep System and CellTracks Analyzer II Instrument revenue - range of between $9 million and $10 million (excludes estimated 2007 EasyCount System revenue)
* Combined reagent, consumable and service revenue – range of between $5 million and $6.5 million
* Net cash expenditures – range of between $20 million and $22 million

We are increasing the revenue guidance for instrument revenue from a range of between $8 million and $9 million due to a higher than previously anticipated rate of instrument placements in the second half of 2007. We are increasing our guidance for cash expenditures from a range of $17.5 million to $20 million to account for expenditures related to the arbitration against Veridex. For the nine months ended September 30, 2007, we have incurred $5.4 million in arbitration-related expenses. While it is difficult to project the extent of arbitration activities and costs, we expect that these activities and costs will increase over the next 3 to 4 months.

The financial guidance estimates shown above reflect current expectations of Immunicon’s management based on available information. These statements are forward-looking and actual results may differ materially, including as a result of the factors more specifically referenced below in the discussion regarding “forward-looking statements.” Estimating the items above is inherently difficult.

A summary of instrument shipments and instruments sold for revenue recognition purposes for the period from product launch to September 30, 2007 is shown below:


Cumulative as of Three months ended Cumulative as of
June 30, 2007 September 30, 2007 September 30, 2007

Instrument shipments


Cell analyzers 107 23 130

CellTracks AutoPreps 97 22 119


Instruments sold (1)


Cell analyzers 102 21 123

CellTracks AutoPreps 87 20 1
http://biz.yahoo.com/bw/071102/20071102005114.html?.v=1

7-Nov-07 Caris & Company Downgrade from Above Average to Average

Parabolic SAR Buy Signals (IMMC)

Stocks in a New Uptrend (Aroon) (IMMC)

Stocks in a New Uptrend (ADX) (IMMC)

Moved Above Upper Bollinger Band (IMMC)

Parabolic SAR Buy Signals (IMMC)

Parabolic SAR Buy Signals (IMMC)

Immunicon Announces Laboratory Services and Assay Development Agreements with Merck Serono

Immunicon Corporation (NASDAQ-GM:IMMC) announced today that it has entered into laboratory service and assay development agreements with Merck Serono, Geneva, Switzerland, a division of Merck KGaA, Darmstadt, Germany. The agreements cover laboratory service testing and development of specialized biomarker assays based on Circulating Tumor Cells (CTCs), within the scope of an early clinical drug study. With the results of the tests performed within the scope of the agreements, researchers at Merck Serono may be able to examine biological activity of the drug(s) being evaluated, both early in the course of treatment and early in the drug development process. Moreover, the new assays developed under the agreement may eventually help doctors to identify patients who have a high probability of responding to the drug under investigation.

Leon Terstappen, M.D. PhD, Chief Scientific Officer of Immunicon, said, “We are looking forward to starting this collaboration with Merck Serono. The ability to ‘interrogate’ the extremely rare circulating cells once isolated from peripheral blood gives unprecedented opportunities to see ‘real-time’ what is happening with tumor cells in patients upon exposure to investigational drugs. On top of testing kinetics of circulating tumor cells, which may give important information on drug activity itself, the assays we will be developing in this project may provide predictive information as to who is likely to react to the drug and who is not. This can ultimately be an important tool on the way to personalizing cancer therapy.”

Byron D. Hewett, President and Chief Executive Officer of Immunicon, commented, “We are very pleased to work with Merck Serono, a global company focusing on innovative small molecules and biopharmaceuticals. The laboratory service testing and the specialized assay we will develop is yet another example of the value of rare cell isolation and analysis in oncology drug development studies.”

About Immunicon Corporation

Immunicon Corporation is developing and commercializing proprietary cell- and molecular-based human diagnostic and life science research products with an initial focus on cancer disease management. Immunicon has developed platform technologies for selection and analysis of rare cells in blood, such as circulating tumor cells and circulating endothelial cells that are important in many diseases and biological processes. Immunicon’s products and underlying technology platforms also have application in the clinical development of cancer drugs and in cancer research and may have applications in other fields of medicine, such as cardiovascular and infectious diseases. For more information, please visit www.immunicon.com

Hammer Patterns (IMMC)

Immunicon Corp files for $75 million mixed shelf
Wed Aug 22, 2007 4:56PM EDT

WASHINGTON, Aug 22 (Reuters) - Immunicon Corp (IMMC.O: Quote, Profile, Research) filed with regulators on Wednesday to periodically sell up to $75 million in debt securities, common and preferred stock, and other securities.

The drug developer said in a registration statement with the U.S. Securities and Exchange Commission that it will use the proceeds for working capital and other other corporate purposes.

Under a shelf registration, a company may sell securities in one or more separate offerings with the size, price and terms to be determined at the time of sale. (Reporting by Karey Wutkowski)

IMMC Finding bottom here?

$4.00 by mid JULY

Bought a bunch more today on pull back. Waiting for rebound soon.

right ....

you never know!

Order in @ $2.97 .... jus n case ....

Get ready to RUMBLE!!!